Mostrando 401 - 420 Resultados de 1,481 Para Buscar '"pneumococcal disease"', tiempo de consulta: 0.26s Limitar resultados
  1. 401
    “…INTRODUCTION: Studies that estimate the economic burden of pediatric pneumococcal disease often only report direct medical costs and omit indirect non-medical costs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective
  2. 402
    “…We estimated case numbers for invasive pneumococcal disease using data from the national laboratory-based surveillance, adjusted for specimen-taking practices. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in South Africa
  3. 403
    “…We assessed the vaccination effectiveness (VE) of the PCV13 in preventing invasive pneumococcal disease (IPD) in children aged 7–59 months in a population with suboptimal vaccination coverage of 55%. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study
  4. 404
    “…Our results suggest that this emerging serotype could represent a real threat among pneumococcal disease in the near future. DISCLOSURES: All authors: No reported disclosures.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1429. Emergence of Multidrug-resistant Serotype 24 Among Children Under 2 Years Old With Invasive Pneumococcal Disease After the Introduction of PCV13 in Argentina
  5. 405
    “…BACKGROUND: Invasive Pneumococcal Disease (IPD) is a major public health concern. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales
  6. 406
    “…To prevent invasive pneumococcal disease (IPD), pneumococcal conjugate vaccines (PCVs) have been implemented in many countries; however, many cases of IPD still occur and can be attributable to nonvaccine serotypes of Streptococcus pneumoniae. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017
  7. 407
    “…BACKGROUND: Invasive pneumococcal disease remains an important health priority owing to increasing disease incidence caused by pneumococci expressing non-vaccine serotypes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study
  8. 408
    “…Significant reduction in the incidence rates of both vaccine and non-vaccine serotype invasive pneumococcal disease among children and adults during the COVID-19 pandemic were observed after the implementation of non-pharmaceutical interventions https://bit.ly/36CAute…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Serotype transmission dynamics and reduced incidence of invasive pneumococcal disease caused by different serotypes after implementation of non-pharmaceutical interventions during COVID-19 pandemic
  9. 409
    “…Among older adults aged ≥65 years, the trial established 13-valent pneumococcal conjugate vaccine (PCV13) efficacy in preventing first episodes of bacteremic and nonbacteremic pneumococcal vaccine serotype (VT) community acquired pneumonia (CAP), and of vaccine serotype invasive pneumococcal disease (VT-IPD). Since the publication of the original trial results, 15 additional publications have extended the analyses. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
  10. 410
    “…Streptococcus pneumoniae can commonly cause otitis media, sinusitis, pneumonia, or meningitis; however, these infections less frequently can develop into invasive pneumococcal disease (IPD). Vaccination for the prevention of pneumococcal disease has significantly decreased complications from severe infections, including pneumonia, meningitis, and IPD, in patients with certain risk factors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Invasive Pneumococcal Disease Secondary to Acute Otitis Media in a High-Risk Patient: A Case Report and Review of Recent Changes to Pneumococcal Immunization Guidelines
  11. 411
    “…Robust immune responses to all 20 vaccine serotypes 1 month after PCV20 were observed in adults with increased risk of serious pneumococcal disease. CLINICAL TRIAL REGISTRATION: NCT03760146, NCT03828617.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
  12. 412
    “…BACKGROUND: Chronic conditions increase the risk of invasive pneumococcal diseases (IPD). Pneumococcal vaccination remarkably reduced IPD morbimortality in vulnerable populations. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Chronic medical conditions associated with invasive pneumococcal diseases in inpatients in teaching hospitals in São Paulo city: Estimating antimicrobial susceptibility and serotype-coverage of pneumococcal vaccines
  13. 413
    “…METHODS: We used the indirect cohort method to estimate VE of PCV13 against vaccine-type invasive pneumococcal disease among children < 5 years in the U.S. from May 1, 2010 to December 31, 2019. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1718. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study
  14. 414
    “…These analyses should be conducted in specific geographical areas and should be aimed to evolution of invasive pneumococcal disease (IPD), by age groups, clinical presentation, and vaccine serotypes (and non-vaccine serotypes to detect possible replacement). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccines
  15. 415
    por Cohen, Cheryl, von Mollendorf, Claire, de Gouveia, Linda, Naidoo, Nireshni, Meiring, Susan, Quan, Vanessa, Nokeri, Vusi, Fortuin-de Smit, Melony, Malope-Kgokong, Babatyi, Moore, David, Reubenson, Gary, Moshe, Mamokgethi, Madhi, Shabir A., Eley, Brian, Hallbauer, Ute, Kularatne, Ranmini, Conklin, Laura, O'Brien, Katherine L., Zell, Elizabeth R., Klugman, Keith, Whitney, Cynthia G., von Gottberg, Anne, Moore, David, Verwey, Charl, Varughese, Sheeba, Archary, Moherndran, Naby, Fathima, Dawood, Khathija, Naidoo, Ramola, Elliott, Gene, Hallbauer, Ute, Eley, Brian, Nuttall, James, Cooke, Louise, Finlayson, Heather, Rabie, Helena, Whitelaw, Andrew, Perez, Dania, Jooste, Pieter, Naidoo, Dhamiran, Kularatne, Ranmini, Reubenson, Gary, Cohen, Cheryl, de Gouveia, Linda, du Plessis, Mignon, Govender, Nevashan, Meiring, Susan, Quan, Vanessa, von Mollendorf, Claire, Fortuin-de Smidt, Melony, Naidoo, Nireshni, Malope-Kgokong, Babatyi, Nokeri, Vusi, Ncha, Relebohile, Lindani, Sonwabo, von Gottberg, Anne, Spies, Barry, Sono, Lino, Maredi, Phasweni, Hamese, Ken, Moshe, Mamokgethi, Nchabeleng, Maphosane, Ngcobo, Ntombenhle, van den Heever, Johann, Madhi, Shabir, Conklin, Laura, Verani, Jennifer, Whitney, Cynthia, Zell, Elizabeth, Loo, Jennifer, Nelson, George, Klugman, Keith, O'Brien, Katherine
    Publicado 2014
    “…We estimated the effectiveness of ≥2 PCV7 doses against invasive pneumococcal disease (IPD) in human immunodeficiency virus (HIV)–infected and -uninfected children. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in HIV-Infected and -Uninfected Children in South Africa: A Matched Case-Control Study
  16. 416
    “…Although, neither of the PCVs were used significantly in adults, changes in adult invasive pneumococcal disease (IPD) were expected due to herd protection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012–2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes
  17. 417
    “…BACKGROUND: Rates of invasive pneumococcal disease (IPD) among indigenous populations remain substantially higher than their non-indigenous counterparts. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Changing Epidemiology of Invasive Pneumococcal Disease Among the Indigenous and Non-indigenous Population of Northwestern Ontario, Canada, from 2006 Through 2015 and Emergence of Non-vaccine Serotypes
  18. 418
    “…We analyzed data from the Toronto Invasive Bacterial Diseases Network (TIBDN) to ask whether PCV13-type invasive pneumococcal disease (IPD) in adults persists in our population. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2716. Persistence of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Serotypes in Invasive Pneumococcal Disease in Adults in Southern Ontario Canada Despite Routine Pediatric Vaccination
  19. 419
    “…The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study
  20. 420
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    176. Selected Impact of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) at Eight Children’s Hospitals in the United States. 2014–2019
Herramientas de búsqueda: RSS